Your browser doesn't support javascript.
loading
Impacts of rifaximin and midodrine on morbidity, mortality, and quality of life in patients with decompensated liver cirrhosis.
Elsabaawy, Maha Mohammad; Assem, Medhat; Badran, Hanaa; Mahmoud, Asmaa; Elsabaawy, Dalia; Ragab, Amr.
Affiliation
  • Elsabaawy MM; Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebeen El-Koom, Egypt.
  • Assem M; Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebeen El-Koom, Egypt.
  • Badran H; Internal Medicine Department, Faculty of Medicine, Bisha University, Saudi Arabia.
  • Mahmoud A; Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebeen El-Koom, Egypt.
  • Elsabaawy D; Internal medicine Department, Banha Teaching Hospital, Banha.
  • Ragab A; Clinical Pharmacy Department, Pharmacy College, Menoufia University, Shebeen El-Koom, Egypt.
Eur J Gastroenterol Hepatol ; 36(8): 1022-1028, 2024 Aug 01.
Article in En | MEDLINE | ID: mdl-38973543

Full text: 1 Database: MEDLINE Main subject: Quality of Life / Rifamycins / Rifaximin / Liver Cirrhosis / Midodrine Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Year: 2024 Type: Article

Full text: 1 Database: MEDLINE Main subject: Quality of Life / Rifamycins / Rifaximin / Liver Cirrhosis / Midodrine Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Year: 2024 Type: Article